Pradžia › Mielodisplastiniai sindromai › Washington › Seattle
Mielodisplastiniai sindromai klinikiniai tyrimai Seattle, WA
Vienas tyrimas dėl Mielodisplastiniai sindromai ieško dalyvių vietoje Seattle arba jos apylinkėse. Atidarykite jį, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Renkami dalyviai2 fazė
- Swedish Medical Center-First Hill, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Renkami dalyviai2 fazė
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Renkami dalyviai1/2 fazė
- University of Washington, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Renkami dalyviai1 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Renkami dalyviaiStebimasis tyrimas
- Fred Hutchinson, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Renkami dalyviai1/2 fazė
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Renkami dalyviai2 fazė
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Renkami dalyviai1 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Renkami dalyviai2/3 fazė
- Seattle Cancer Care Alliance, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Renkami dalyviai1/2 fazė
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Renkami dalyviai2 fazė
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Renkami dalyviai2 fazė
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Renkami dalyviaiStebimasis tyrimas
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Renkami dalyviai1 fazė
- Fred Hutchinson Cancer Center, Seattle
Mielodisplastiniai sindromai tyrimai kituose miestuose
- Houston, TX43 tyrimai
- Baldwin Park, CA26 tyrimai
- New York City, NY21 tyrimas
- Washington, DC20 tyrimai
- Boston, MA19 tyrimai
- Tampa, FL19 tyrimai
- Miami, FL17 tyrimai
- Columbus, OH14 tyrimai
- Durham, NC14 tyrimai
- Chicago, IL13 tyrimai
- Atlanta, GA13 tyrimai
- St. Louis, MO13 tyrimai
Kiti tyrimai Seattle
- Nedidelinių ląstelių plaučių vėžys53 tyrimai
- Vėžys (visų tipų)49 tyrimai
- Prostatos vėžys42 tyrimai
- Ūmi mieloidinė leukemija40 tyrimai
- Krūties vėžys39 tyrimai
- Metastatinis vėžys39 tyrimai
- Storosios ir tiesiosios žarnos vėžys34 tyrimai
- Plaučių vėžys33 tyrimai
- Kiaušidžių vėžys30 tyrimai
- Kartotinė mieloma22 tyrimai
- Ūmi limfoblastinė leukemija21 tyrimas
- Šlapimo pūslės vėžys21 tyrimas
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.